DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

17 Drugs in Development

17 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

DIGITAL CONTENT

24 NEWS #PharmaBuzz

media
24 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1308672-74-3, Surufatinib, N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide, Hmpl-012, Kdr-in-1, 1816307-67-1

Molecular Formula

C₂₄H₂₈N₆O₃S

Molecular Weight

480.6 g/mol

InChI Key

TTZSNFLLYPYKIL-UHFFFAOYSA-N

FDA UNII

B2K5L1L8S9

Sulfatinib is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.

1 2D Structure

Surufatinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide

2.1.2 InChI

InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29)

2.1.3 InChI Key

TTZSNFLLYPYKIL-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C

2.2 Other Identifiers

2.2.1 UNII

B2K5L1L8S9

2.3 Synonyms

2.3.1 MeSH Synonyms

1. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

2. Surufatinib

2.3.2 Depositor-Supplied Synonyms

1. 1308672-74-3

2. Surufatinib

3. N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

4. Hmpl-012

5. Kdr-in-1

6. 1816307-67-1

7. Hmpl012

8. Surufatinib [inn]

9. Surufatinib [usan]

10. B2k5l1l8s9

11. N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide

12. Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1h-indol-5-yl)oxy)-2-pyrimidinyl)amino)-

13. Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1h-indol-5-yl)oxy]-2-pyrimidinyl]amino]-

14. Sulanda

15. N-[2-(dimethylamino)ethyl]-1-[3-({4-[(2-methyl-1h-indol-5-yl)oxy]pyrimidin-2-yl}amino)phenyl]methanesulfonamide

16. Sulfatinib [who-dd]

17. Sulfatinib; Hmpl-012

18. Unii-b2k5l1l8s9

19. Surufatinib [who-dd]

20. Gtpl9769

21. Schembl1822601

22. Chembl4297190

23. Bcp14757

24. Ex-a2524

25. Nsc797937

26. Who 10349

27. Akos030632837

28. Zinc117218067

29. Cs-5949

30. Db15106

31. Nsc-797937

32. Ac-35852

33. As-74954

34. Hmpl-012;hmpl 012;hmpl012

35. Hy-12297

36. Vegfr2 Inhibitor [wo2011060746]

37. D71057

38. A926546

39. N-(2-(dimethylamino) Ethyl)-1-(3-((4-((2-methyl-1h-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide

40. N-(2-(dimethylamino) Ethyl)-1-(3-((4-(2-methyl-1h-indol-5-yloxy) Pyrimidin-2-yl) Amino) Phenyl) Methanesulfonamide

2.4 Create Date

2011-06-06

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₈N₆O₃S
Molecular Weight	480.6 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	10
Exact Mass	480.19435995 g/mol
Monoisotopic Mass	480.19435995 g/mol
Topological Polar Surface Area	121 Å²
Heavy Atom Count	34
Formal Charge	0
Complexity	733
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms), Treatment of malignant neoplasms of haematopoietic and lymphoid tissue

Drugs in Development